BioStreet Announces Top 20 Pharmaceutical Companies Now Using BioStreet Dealmaking Service

More Than 230 Pharmaceutical and Biotech Companies Are Accessing Online

Technology Exchange to Identify Licensing and Partnering Opportunities



Apr 20, 2001, 01:00 ET from BioStreet

    HONOLULU and SOUTH SAN FRANCISCO, Calif., April 20 /PRNewswire Interactive
 News Release/ -- BioStreet(TM), the premier life sciences partnering company,
 announced today at BIO AsiaPacific, an industry partnering conference, that
 more than 230 pharmaceutical and biotechnology companies, including all
 20 of the top 20 revenue-producing drug development companies, are accessing
 BioStreet's DealXchange(TM).
     DealXchange is an online marketplace exchange that features high-quality
 life sciences product licensing opportunities that have been fully assessed
 and characterized by BioStreet's scientific staff and advisors.
     "We are extremely pleased with the rapid and wide acceptance of BioStreet
 and its innovative approach to life sciences dealmaking, which is designed to
 improve upon the imperfect processes used by dealmakers that often do not
 guarantee the best possible deals for a company," said Dick Haiduck,
 BioStreet's president and chief executive officer.  "BioStreet's services help
 empower dealmakers to accelerate the time it takes to implement and improve
 the quality of key partnering processes so that better deals can be done
 sooner."
 
     BioStreet Announces New Listing Agreements
     BioStreet also announced that it has signed agreements to list partnerable
 technologies for BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) and
 privately-held Message Pharmaceuticals Inc. on DealXchange.  The agreements
 take effect immediately.
     BioMarin has listed a novel investigational agent rhASB
 (a recombinant human enzyme) as an enzyme replacement therapy for the
 treatment of MPS-VI, a type of mucopolysaccharidosis that is a debilitating
 life-threatening genetic disease.  This compound currently is being evaluated
 in a Phase I clinical trial, and BioMarin is seeking a strategic partner to
 handle all aspects of its commercialization, including worldwide sales,
 marketing, distribution and reimbursement.  This late-stage product candidate
 already in the clinic has been granted orphan drug status in the United States
 and Europe, which means accelerated regulatory review and approval.
     Message has listed a fully integrated proprietary platform technology
 called SCRIBE(TM), a flexible process that leads to the discovery of drugs
 that either enhance (e.g., growth factors) or suppress (e.g., TNF) expression
 of the protein target of choice.  Since so many messenger RNAs are regulated,
 Message's technology is applicable to all therapeutic areas.  This unique
 focus on messenger RNA regulation allows for the discovery and exploitation of
 new disease genes, emerging from today's genomics efforts.  Message is seeking
 collaborations with leading companies.
     "These compounds and programs represent real in-licensing opportunities
 for companies seeking to enhance their product portfolios and pipelines," said
 Benjamin Chen, Ph.D., BioStreet's chief scientific officer.  "At BioStreet,
 our experienced scientific staff and advisors are doing the scientific leg
 work necessary to fully evaluate and qualify our technology and product
 listings.  We believe this is why so many of the leading pharmaceutical and
 biotechnology are using our service, because they can count on the quality of
 our listings."
 
     DealXchange - Matching Buyers and Sellers
     Through agreements with U.S. life sciences companies, BioStreet lists
 pre-screened high-quality partnerable technologies and products in a
 standardized format, which was developed in collaboration with many of the
 companies now using DealXchange.  DealXchange efficiently matches the needs of
 companies acquiring technology with those seeking partnerships for their
 technology via a database search engine or an automatic, pre-defined client
 criteria.  DealXchange facilitates the initial exchange of non-confidential
 information in a context defined to further the partnering interests of both
 parties and provides a variety of presentation techniques that ensure quality
 communication of technology capabilities via the internet.  The result is that
 better deals are done sooner, because companies move more quickly into
 partnering discussions that are based on a meaningful exchange of relevant
 information.
 
     BioStreet - Better Deals, Done Sooner
     BioStreet is committed to reinventing the partnering process for both
 sellers and buyers in the life sciences industry by providing solutions that
 enable clients to achieve better deals, done sooner.  Its lead products,
 DealXchange and DealXpert(TM) (previously, Omniscience Life Sciences), an
 online due diligence resource currently under development, have been designed
 to establish new industry standards and processes for identifying and
 assessing partnering opportunities.  BioStreet is privately held and based in
 South San Francisco.
     For a demonstration and more information, visit the company's web site at
 www.BioStreet.com or call 650-246-8775.
 
                      MAKE YOUR OPINION COUNT - Click Here
                http://tbutton.prnewswire.com/prn/11690X94537156
 
 

SOURCE BioStreet
    HONOLULU and SOUTH SAN FRANCISCO, Calif., April 20 /PRNewswire Interactive
 News Release/ -- BioStreet(TM), the premier life sciences partnering company,
 announced today at BIO AsiaPacific, an industry partnering conference, that
 more than 230 pharmaceutical and biotechnology companies, including all
 20 of the top 20 revenue-producing drug development companies, are accessing
 BioStreet's DealXchange(TM).
     DealXchange is an online marketplace exchange that features high-quality
 life sciences product licensing opportunities that have been fully assessed
 and characterized by BioStreet's scientific staff and advisors.
     "We are extremely pleased with the rapid and wide acceptance of BioStreet
 and its innovative approach to life sciences dealmaking, which is designed to
 improve upon the imperfect processes used by dealmakers that often do not
 guarantee the best possible deals for a company," said Dick Haiduck,
 BioStreet's president and chief executive officer.  "BioStreet's services help
 empower dealmakers to accelerate the time it takes to implement and improve
 the quality of key partnering processes so that better deals can be done
 sooner."
 
     BioStreet Announces New Listing Agreements
     BioStreet also announced that it has signed agreements to list partnerable
 technologies for BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) and
 privately-held Message Pharmaceuticals Inc. on DealXchange.  The agreements
 take effect immediately.
     BioMarin has listed a novel investigational agent rhASB
 (a recombinant human enzyme) as an enzyme replacement therapy for the
 treatment of MPS-VI, a type of mucopolysaccharidosis that is a debilitating
 life-threatening genetic disease.  This compound currently is being evaluated
 in a Phase I clinical trial, and BioMarin is seeking a strategic partner to
 handle all aspects of its commercialization, including worldwide sales,
 marketing, distribution and reimbursement.  This late-stage product candidate
 already in the clinic has been granted orphan drug status in the United States
 and Europe, which means accelerated regulatory review and approval.
     Message has listed a fully integrated proprietary platform technology
 called SCRIBE(TM), a flexible process that leads to the discovery of drugs
 that either enhance (e.g., growth factors) or suppress (e.g., TNF) expression
 of the protein target of choice.  Since so many messenger RNAs are regulated,
 Message's technology is applicable to all therapeutic areas.  This unique
 focus on messenger RNA regulation allows for the discovery and exploitation of
 new disease genes, emerging from today's genomics efforts.  Message is seeking
 collaborations with leading companies.
     "These compounds and programs represent real in-licensing opportunities
 for companies seeking to enhance their product portfolios and pipelines," said
 Benjamin Chen, Ph.D., BioStreet's chief scientific officer.  "At BioStreet,
 our experienced scientific staff and advisors are doing the scientific leg
 work necessary to fully evaluate and qualify our technology and product
 listings.  We believe this is why so many of the leading pharmaceutical and
 biotechnology are using our service, because they can count on the quality of
 our listings."
 
     DealXchange - Matching Buyers and Sellers
     Through agreements with U.S. life sciences companies, BioStreet lists
 pre-screened high-quality partnerable technologies and products in a
 standardized format, which was developed in collaboration with many of the
 companies now using DealXchange.  DealXchange efficiently matches the needs of
 companies acquiring technology with those seeking partnerships for their
 technology via a database search engine or an automatic, pre-defined client
 criteria.  DealXchange facilitates the initial exchange of non-confidential
 information in a context defined to further the partnering interests of both
 parties and provides a variety of presentation techniques that ensure quality
 communication of technology capabilities via the internet.  The result is that
 better deals are done sooner, because companies move more quickly into
 partnering discussions that are based on a meaningful exchange of relevant
 information.
 
     BioStreet - Better Deals, Done Sooner
     BioStreet is committed to reinventing the partnering process for both
 sellers and buyers in the life sciences industry by providing solutions that
 enable clients to achieve better deals, done sooner.  Its lead products,
 DealXchange and DealXpert(TM) (previously, Omniscience Life Sciences), an
 online due diligence resource currently under development, have been designed
 to establish new industry standards and processes for identifying and
 assessing partnering opportunities.  BioStreet is privately held and based in
 South San Francisco.
     For a demonstration and more information, visit the company's web site at
 www.BioStreet.com or call 650-246-8775.
 
                      MAKE YOUR OPINION COUNT - Click Here
                http://tbutton.prnewswire.com/prn/11690X94537156
 
 SOURCE  BioStreet